1. Home
  2. XNCR vs CERT Comparison

XNCR vs CERT Comparison

Compare XNCR & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xencor Inc.

XNCR

Xencor Inc.

HOLD

Current Price

$11.87

Market Cap

881.9M

Sector

Health Care

ML Signal

HOLD

CERT

Certara Inc.

HOLD

Current Price

$5.90

Market Cap

860.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
XNCR
CERT
Founded
1997
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
881.9M
860.9M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
XNCR
CERT
Price
$11.87
$5.90
Analyst Decision
Buy
Buy
Analyst Count
9
10
Target Price
$22.33
$11.67
AVG Volume (30 Days)
648.0K
3.5M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
65.36
87.50
EPS
N/A
N/A
Revenue
$125,576,000.00
$418,838,000.00
Revenue This Year
N/A
$4.18
Revenue Next Year
$4.80
$5.39
P/E Ratio
N/A
N/A
Revenue Growth
13.65
8.75
52 Week Low
$6.92
$4.45
52 Week High
$18.69
$13.88

Technical Indicators

Market Signals
Indicator
XNCR
CERT
Relative Strength Index (RSI) 49.68 58.09
Support Level $10.83 $5.19
Resistance Level $12.87 $6.47
Average True Range (ATR) 0.58 0.36
MACD 0.02 0.11
Stochastic Oscillator 49.60 88.68

Price Performance

Historical Comparison
XNCR
CERT

About XNCR Xencor Inc.

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

Share on Social Networks: